924 related articles for article (PubMed ID: 29705182)
21. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
22. Optimizing glioblastoma temozolomide chemotherapy employing lentiviral-based anti-MGMT shRNA technology.
Viel T; Monfared P; Schelhaas S; Fricke IB; Kuhlmann MT; Fraefel C; Jacobs AH
Mol Ther; 2013 Mar; 21(3):570-9. PubMed ID: 23319055
[TBL] [Abstract][Full Text] [Related]
23. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
Chen Z; Wei X; Shen L; Zhu H; Zheng X
Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
[TBL] [Abstract][Full Text] [Related]
24. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA
Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610
[TBL] [Abstract][Full Text] [Related]
25. Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma.
Gupta SK; Kizilbash SH; Carlson BL; Mladek AC; Boakye-Agyeman F; Bakken KK; Pokorny JL; Schroeder MA; Decker PA; Cen L; Eckel-Passow JE; Sarkar G; Ballman KV; Reid JM; Jenkins RB; Verhaak RG; Sulman EP; Kitange GJ; Sarkaria JN
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26615020
[TBL] [Abstract][Full Text] [Related]
26. Overexpression miR-486-3p Promoted by Allicin Enhances Temozolomide Sensitivity in Glioblastoma Via Targeting MGMT.
Wu H; Li X; Zhang T; Zhang G; Chen J; Chen L; He M; Hao B; Wang C
Neuromolecular Med; 2020 Sep; 22(3):359-369. PubMed ID: 32086739
[TBL] [Abstract][Full Text] [Related]
27. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
[TBL] [Abstract][Full Text] [Related]
28. LncRNA UCA1/miR-182-5p/MGMT axis modulates glioma cell sensitivity to temozolomide through MGMT-related DNA damage pathways.
Cheng M; Wang Q; Chen L; Zhao D; Tang J; Xu J; He Z
Hum Pathol; 2022 May; 123():59-73. PubMed ID: 35219686
[TBL] [Abstract][Full Text] [Related]
29. Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells.
Ryu CH; Yoon WS; Park KY; Kim SM; Lim JY; Woo JS; Jeong CH; Hou Y; Jeun SS
J Biomed Biotechnol; 2012; 2012():987495. PubMed ID: 22701311
[TBL] [Abstract][Full Text] [Related]
30. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
Wu Q; Berglund AE; Macaulay RJ; Etame AB
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894860
[TBL] [Abstract][Full Text] [Related]
31. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
Montaldi AP; Lima SCG; Godoy PRDV; Xavier DJ; Sakamoto-Hojo ET
Oncol Rep; 2020 Nov; 44(5):2275-2287. PubMed ID: 32901889
[TBL] [Abstract][Full Text] [Related]
32. Magnolol and Temozolomide exhibit a synergistic anti-glioma activity through MGMT inhibition.
Kundu M; Das S; Nandi S; Dhara D; Mandal M
Biochim Biophys Acta Mol Basis Dis; 2023 Oct; 1869(7):166782. PubMed ID: 37286145
[TBL] [Abstract][Full Text] [Related]
33. Lnc-TALC promotes O
Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C
Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma.
Tian T; Mingyi M; Qiu X; Qiu Y
Oncotarget; 2016 Nov; 7(48):79584-79595. PubMed ID: 27792996
[TBL] [Abstract][Full Text] [Related]
35. Temozolomide Induces the Acquisition of Invasive Phenotype by O6-Methylguanine-DNA Methyltransferase (MGMT)
Kochanowski P; Catapano J; Pudełek M; Wróbel T; Madeja Z; Ryszawy D; Czyż J
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923767
[TBL] [Abstract][Full Text] [Related]
36. Glioblastoma Recurrence and the Role of O
Storey K; Leder K; Hawkins-Daarud A; Swanson K; Ahmed AU; Rockne RC; Foo J
JCO Clin Cancer Inform; 2019 Feb; 3():1-12. PubMed ID: 30758983
[TBL] [Abstract][Full Text] [Related]
37. NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells.
Tsuji S; Nakamura S; Shoda K; Yamada T; Shimazawa M; Nakayama N; Iwama T; Hara H
J Neurooncol; 2022 Nov; 160(2):375-388. PubMed ID: 36308592
[TBL] [Abstract][Full Text] [Related]
38. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.
Kitange GJ; Mladek AC; Carlson BL; Schroeder MA; Pokorny JL; Cen L; Decker PA; Wu W; Lomberk GA; Gupta SK; Urrutia RA; Sarkaria JN
Clin Cancer Res; 2012 Aug; 18(15):4070-9. PubMed ID: 22675172
[TBL] [Abstract][Full Text] [Related]
40. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]